Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,212 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Carbohydrate + Protein Clear all
Completed Phase 1Phase 2 Interventional

The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease

NCT01676103
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tyrosine, Placebo Comparator:Sugar Pill
Dietary Supplement · Other
Lead sponsor
New York Institute of Technology
Other
Eligibility
50 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 8, 2026, 2:15 PM EDT
Suspended Early Phase 1 Interventional Accepts healthy volunteers

Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome

NCT03722303
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Fat Injection, Steroid Injection
Other · Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 8, 2026, 2:15 PM EDT
Withdrawn Phase 2 Interventional

High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease

NCT01656590
View directory record Official record
Conditions
Glycogen Storage Disease Type II
Interventions
High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding
Other
Lead sponsor
Columbia University
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 8, 2026, 2:15 PM EDT
Active, not recruiting Phase 1 Interventional

Rapid Administration Pilot for Infusing Dinutuximab

NCT05421897
View directory record Official record
Conditions
Neuroblastoma
Interventions
Dinutuximab with Chemotherapy
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 8, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

NCT03646123
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, G-CSF, nivolumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
12 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
55
States / cities
Fountain Valley, California • Aurora, Colorado • Colorado Springs, Colorado + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 8, 2026, 2:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

EMS Providers' Health Initiative Study

NCT05153759
View directory record Official record
Conditions
Shift-work Disorder
Interventions
Meal service
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

NCT02231879
View directory record Official record
Conditions
Myelokathexis, Infections, Neutropenia, Warts, Hypogammaglobulinemia
Interventions
Plerixafor, G-CSF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

NCT02876835
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
161
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Study of CB-183,315 in Participants With Clostridium Difficile Infection

NCT01085591
View directory record Official record
Conditions
Clostridium Difficile Infection, Diarrhea
Interventions
CB-183,315, Placebo, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Washington D.C., District of Columbia • Saint Cloud, Florida • Decatur, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 8, 2026, 2:15 PM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT03749018
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Indolent Non-Hodgkin Lymphoma, Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Nivolumab, Prednisone, Rituximab, Vincristine Sulfate
Drug · Biological
Lead sponsor
David Bond, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

NCT00005585
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
108
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00602225
View directory record Official record
Conditions
Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Promyelocytic Leukemia (M3), Recurrent Adult Acute Myeloid Leukemia
Interventions
clofarabine, cytarabine, filgrastim
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 8, 2026, 2:15 PM EDT
Active, not recruiting Phase 2 Interventional Results available

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

NCT03600350
View directory record Official record
Conditions
Prostate Cancer
Interventions
pTVG-HP, Nivolumab, GM-CSF
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

NCT00968760
View directory record Official record
Conditions
Lymphoma, B-cell Lymphoma
Interventions
Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion, IL-2, Carmustine, Etoposide, Cytarabine, Melphalan
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 8, 2026, 2:15 PM EDT
Withdrawn No phase listed Observational

Use of Antibiotic Carrier in Acute Periprosthetic Infections (APPI) of Total Knee Replacements

NCT02107924
View directory record Official record
Conditions
Infection
Interventions
APPI of TKR-Stimulan
Procedure
Lead sponsor
Michael Muldoon, M.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Sep 8, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional Results available

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

NCT00126191
View directory record Official record
Conditions
Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Methotrexate, Leucovorin, Ifosfamide, Etoposide, Cytarabine, Mesna
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

NCT00014222
View directory record Official record
Conditions
Breast Cancer
Interventions
epoetin alfa, filgrastim, cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride, fluorouracil, paclitaxel
Biological · Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
Up to 60 Years · Female only
Enrollment
2,104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
44
States / cities
Fort Smith, Arkansas • Little Rock, Arkansas • La Jolla, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

NCT00338286
View directory record Official record
Conditions
Breast Cancer, Neoplasm Metastasis
Interventions
Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
2,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
14
States / cities
Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 2 Interventional

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A

NCT01858922
View directory record Official record
Conditions
Hodgkin Disease
Interventions
ABVE-PC, DECA
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 8, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional Results available

Early Metabolic Resuscitation for Septic Shock

NCT03895853
View directory record Official record
Conditions
Multiple Organ Failure, Septic Shock, Severe Sepsis
Interventions
Best Practice, early metabolic resuscitation
Other · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Fiber on Appetite and Digestion Hormones

NCT01050101
View directory record Official record
Conditions
Psychological Phenomena and Processes, Nutrition Physiological Phenomena
Interventions
No fiber, Low GI high fiber viscous meal, Low GI high fiber non-viscous
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 2 Interventional

131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

NCT00293319
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, iobenguane I 131
Biological · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
San Francisco, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 8, 2026, 2:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

NCT05545306
View directory record Official record
Conditions
Obesity, Normal Physiology, Healthy Volunteers
Interventions
+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, fasting, -50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein, -25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 8, 2026, 2:15 PM EDT
Terminated Phase 2Phase 3 Interventional

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

NCT00038805
View directory record Official record
Conditions
Leukemia
Interventions
Mylotarg
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
55 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 8, 2026, 2:15 PM EDT